Alemtuzumab in the treatment of multiple sclerosis: Key clinical trial results and considerations for use

Therapeutic Advances in Neurological Disorders

Volumn 8, Issue 1, 2015, Pages 31-45

  Havrdova, Eva ^a   Horakova, Dana ^a   Kovarova, Ivana ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

Author keywords

alemtuzumab; disease modifying therapy; efficacy; mechanism of action; multiple sclerosis; safety

Indexed keywords

ACICLOVIR; ALEMTUZUMAB; ANTIHISTAMINIC AGENT; ANTIPYRETIC AGENT; ANTITHYROID AGENT; BETA1A INTERFERON; CORTICOSTEROID; FUMARIC ACID DIMETHYL ESTER; GAMMA INTERFERON; IMMUNOGLOBULIN; INTERLEUKIN 12; INTERLEUKIN 17; INTERLEUKIN 21; INTERLEUKIN 23; INTERLEUKIN 27; METHYLPREDNISOLONE; NATALIZUMAB; PLACEBO; RADIOACTIVE IODINE; TERIFLUNOMIDE; THYROID HORMONE;

ABORTION; AUTOIMMUNE DISEASE; AUTOIMMUNE THROMBOCYTOPENIA; B LYMPHOCYTE; BASAL CELL CARCINOMA; BLIGHTED OVUM; BRAIN HEMORRHAGE; BREAST CANCER; CARDIOVASCULAR DISEASE; CHILL; CONGENITAL HEART MALFORMATION; DENDRITIC CELL; DISABILITY; DISEASE ACTIVITY; DISEASE SEVERITY; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG MONITORING; DRUG SAFETY; EXPANDED DISABILITY STATUS SCALE; FATIGUE; FETOTOXICITY; FETUS DEATH; FEVER; GOITER; GRAVES DISEASE; HEADACHE; HEART HYPOPLASIA; HERPES SIMPLEX; HERPES ZOSTER; HOT FLUSH; HUMAN; HYGROMA; HYPERTHYROIDISM; HYPOTHYROIDISM; IDIOPATHIC THROMBOCYTOPENIC PURPURA; IMMUNOPATHOGENESIS; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; INFECTION; INFUSION RELATED REACTION; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY DISEASE; LABORATORY TEST; MEDICAL DECISION MAKING; MELANOMA; MEMORY T LYMPHOCYTE; MONOCYTE; MULTIPLE SCLEROSIS; NATURAL KILLER CELL; NAUSEA; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; RECURRENCE RISK; REGULATORY T LYMPHOCYTE; RESPIRATORY TRACT INFECTION; RETREATMENT; REVIEW; RISK ASSESSMENT; RISK MANAGEMENT; SPONTANEOUS ABORTION; STILLBIRTH; SUBACUTE THYROIDITIS; T LYMPHOCYTE; THORAX PAIN; THROMBOCYTE TRANSFUSION; THYROID CARCINOMA; THYROID DISEASE; THYROIDITIS; URINARY TRACT INFECTION; URTICARIA;

EID: 84921047834     PISSN: 17562856     EISSN: 17562864     Source Type: Journal    
DOI: 10.1177/1756285614563522     Document Type: Review

References (70)

1. Azzopardi L. Thompson S. Harding K. Cossburn M. Robertson N. Compston A. et al. (2014) Predicting autoimmunity after alemtuzumab treatment of multiple sclerosis. J Neurol Neurosurg Psychiatry 85: 795–798.
2. Baranzini S. Jeong M. Butunoi C. Murray R. Bernard C. Oksenberg J. (1999) B cell repertoire diversity and clonal expansion in multiple sclerosis brain lesions. J Immunol 163: 5133–5144.
3. Breslin S. (2007) Cytokine-release syndrome: overview and nursing implications. Clin J Oncol Nurs 11: 37–42.
4. CAMMS Trial Investigators, Coles A. Compston D. Selmaj K. Lake S. Moran S. et al. (2008) Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. N Engl J Med 359: 1786–1801.
5. Clark R. Watanabe R. Teague J. Schlapbach C. Tawa M. Adams N. et al. (2012) Skin effector memory T cells do not recirculate and provide immune protection in alemtuzumab-treated CTCL patients. Sci Transl Med 4: 117ra117.
6. Cohen J. Barkhof F. Comi G. Hartung H. Khatri B. Montalban X. et al. (2010) Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 362: 402–415.
7. Cohen J. Coles A. Arnold D. Confavreux C. Fox E. Hartung H. et al. (2012) Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet 380: 1819–1828.
8. Coles A. Arnold D. Cohen J. Fox E. Giovannoni G. Hartung H. et al. (2014) Efficacy and safety of alemtuzumab in treatment-naive patients with relapsing-remitting MS: four-year follow-up of the CARE-MS I study. Presented at 2014 Joint Meeting of Americas Committee for Treatment and Research in Multiple Sclerosis and European Committee for Treatment and Research in Multiple Sclerosis, September, Boston, MA.
9. Coles A. Compston A. (2014) Product licences for alemtuzumab and multiple sclerosis. Lancet 383: 867–868.
10. Coles A. Fox E. Vladic A. Gazda S. Brinar V. Selmaj K. et al. (2011) Alemtuzumab versus interferon beta-1a in early relapsing-remitting multiple sclerosis: post-hoc and subset analyses of clinical efficacy outcomes. Lancet Neurol 10: 338–348.
11. Coles A. Fox E. Vladic A. Gazda S. Brinar V. Selmaj K. et al. (2012 a) Alemtuzumab more effective than interferon beta-1a at 5-year follow-up of CAMMS 223 clinical trial. Neurology 78: 1069–1078.
12. Coles A. Twyman C. Arnold D. Cohen J. Confavreux C. Fox E. et al. (2012 b) Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. Lancet 380: 1829–1839.
13. Coles A. Wing M. Molyneux P. Paolillo A. Davie C. Hale G. et al. (1999 a) Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis. Ann Neurol 46: 296–304.
14. Coles A. Wing M. Smith S. Coraddu F. Greer S. Taylor C. et al. (1999 b) Pulsed monoclonal antibody treatment and autoimmune thyroid disease in multiple sclerosis. Lancet 354: 1691–1695.
15. Compston A. Coles A. (2008) Multiple sclerosis. Lancet 372: 1502–1517.
16. Confavreux C. O'Connor P. Comi G. Freedman M. Miller A. Olsson T. et al. (2014) Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurol 13: 247–256.
17. Cox A. Thompson S. Jones J. Robertson V. Hale G. Waldmann H. et al. (2005) Lymphocyte homeostasis following therapeutic lymphocyte depletion in multiple sclerosis. Eur J Immunol 35: 3332–3342.
18. Cuker A. Coles A. Sullivan H. Fox E. Goldberg M. Oyuela P. et al. (2011) A distinctive form of immune thrombocytopenia in a phase 2 study of alemtuzumab for the treatment of relapsing-remitting multiple sclerosis. Blood 118: 6299–6305.
19. Cuker A. Palmer J. Oyuela P. Margolin D. Bass A. (2014) Successful detection and management of immune thrombocytopenia in alemtuzumab-treated patients with active relapsing-remitting multiple sclerosis Neurology 82: P2.198.
20. Daniels G. Vladic A. Brinar V. Zavalishin I. Valente W. Oyuela P. et al. (2014) Alemtuzumab-related thyroid dysfunction in a phase 2 trial of patients with relapsing-remitting multiple sclerosis. J Clin Endocrinol Metab 99: 80–89.
21. Fletcher J. Lonergan R. Costelloe L. Kinsella K. Moran B. O'Farrelly C. et al. (2009) CD39+Foxp3+ regulatory T cells suppress pathogenic Th 17 cells and are impaired in multiple sclerosis. J Immunol 183: 7602–7610.
22. Fox R. Miller D. Phillips J. Hutchinson M. Havrdova E. Kita M. et al. (2012) Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med 367: 1087–1097.
23. Genzyme Corporation (2007) Campath (alemtuzumab). Full prescribing information. Cambridge, MA. Available at http://www.campath.com/pdfs/Full_Prescribing_Information_Brochure.pdf [accessed 15 April 2014].
24. Genzyme Europe (2007) MabCampath. Summary of product characteristics. Naarden, The Netherlands: Genzyme Europe BV.
25. Genzyme Therapeutics (2013) LEMTRADA summary of product characteristics. Oxford, UK: Genzyme Therapeutics Ltd.
26. Genzyme Corporation (2014) LEMTRADA (alemtuzumab). Full prescribing information. Cambridge, MA: Genzyme Corporation. Available at http://products.sanofi.us/lemtrada/lemtrada.pdf [accessed 2 December 2014].
27. Gold R. Kappos L. Arnold D. Bar-Or A. Giovannoni G. Selmaj K. et al. (2012) Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med 367: 1098–1107.
28. Hale G. Rye P. Warford A. Lauder I. Brito-Babapulle A. (1993) The glycosylphosphatidylinositol-anchored lymphocyte antigen CDw 52 is associated with the epididymal maturation of human spermatozoa. J Reprod Immunol 23: 189–205.
29. Hartung H. Arnold D. Cohen J. Coles A. Confavreux C. Fox E. et al. (2012) Lymphocyte subset dynamics following alemtuzumab treatment in the CARE-MS I study. Presented at 28th Congress of the European Committee for Research and Treatment in Multiple Sclerosis, October, Lyon, France.
30. Hartung H. Arnold D. Cohen J. Coles A. Fox E. Giovannoni G. et al. (2014) Efficacy and safety of alemtuzumab in patients with relapsing-remitting MS who relapsed on prior therapy: four-year follow-up of the CARE-MS II study. Presented at 2014 Joint Meeting of Americas Committee for Treatment and Research in Multiple Sclerosis and European Committee for Treatment and Research in Multiple Sclerosis, September, Boston, MA.
31. Hill-Cawthorne G. Button T. Tuohy O. Jones J. May K. Somerfield J. et al. (2012) Long term lymphocyte reconstitution after alemtuzumab treatment of multiple sclerosis. J Neurol Neurosurg Psychiatry 83: 298–304.
32. Hu Y. Turner M. Shields J. Gale M. Hutto E. Roberts B. et al. (2009) Investigation of the mechanism of action of alemtuzumab in a human CD52 transgenic mouse model. Immunology 128: 260–270.
33. Ibitoye R. Wilkins A. (2014) Thyroid papillary carcinoma after alemtuzumab therapy for MS. J Neurol 261: 1828–1829.
34. Isidoro L. Pires P. Rito L. Cordeiro G. (2014) Progressive multifocal leukoencephalopathy in a patient with chronic lymphocytic leukaemia treated with alemtuzumab. BMJ Case Rep. 8 January 2014. [Epub ahead of print]. DOI: 10.1136/bcr-2013–201781.
35. Jones J. Phuah C. Cox A. Thompson S. Ban M. Shawcross J. et al. (2009) IL-21 drives secondary autoimmunity in patients with multiple sclerosis, following therapeutic lymphocyte depletion with alemtuzumab (Campath-1H). J Clin Invest 119: 2052–2061.
36. Jones J. Thompson S. Loh P. Davies J. Tuohy O. Curry A. et al. (2013) Human autoimmunity after lymphocyte depletion is caused by homeostatic T-cell proliferation. Proc Natl Acad Sci U S A 110: 20200–20205.
37. Kappos L. Radue E. O'Connor P. Polman C. Hohlfeld R. Calabresi P. et al. (2010) A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 362: 387–401.
38. Kasper L. Arnold D. Coles A. Hartung H. Havrdova E. Selmaj K. et al. (2013) Lymphocyte subset dynamics following alemtuzumab treatment in the CARE-MS II study. P531. Presented at 29th Congress of the European Committee for Research and Treatment in Multiple Sclerosis, October, Copenhagen, Denmark.
39. Kebir H. Kreymborg K. Ifergan I. Dodelet-Devillers A. Cayrol R. Bernard M. et al. (2007) Human TH 17 lymphocytes promote blood-brain barrier disruption and central nervous system inflammation. Nat Med 13: 1173–1175.
40. Keough M. Yong V. (2013) Remyelination therapy for multiple sclerosis. Neurotherapeutics 10: 44–54.
41. King C. Ilic A. Koelsch K. Sarvetnick N. (2004) Homeostatic expansion of T cells during immune insufficiency generates autoimmunity. Cell 117: 265–277.
42. Kousin-Ezewu O. Azzopardi L. Parker R. Tuohy O. Compston A. Coles A. et al. (2014) Accelerated lymphocyte recovery after alemtuzumab does not predict multiple sclerosis activity. Neurology 82: 2158–2164.
43. Kovarova I. Arnold D. Cohen J. Coles A. Confavreux C. Fox E. et al. (2012) Alemtuzumab pharmacokinetics and pharmacodynamics in Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis I. Presented at 23rd Meeting of the European Neurological Society, June, Prague, Czech Republic.
44. Krumbholz M. Derfuss T. Hohlfeld R. Meinl E. (2012) B cells and antibodies in multiple sclerosis pathogenesis and therapy. Nat Rev Neurol 8: 613–623.
45. Maggi E. Vultaggio A. Matucci A. (2011) Acute infusion reactions induced by monoclonal antibody therapy. Expert Rev Clin Immunol 7: 55–63.
46. Malmeström C. Andersson B. Lycke J. (2014) First reported case of diabetes mellitus type 1 as a possible secondary autoimmune disease following alemtuzumab treatment in MS. J Neurol 261: 2016–2018.
47. Margolin D. Rizzo M. Smith G. Arnold D. Coles A. Hartung H. et al. (2013) Alemtuzumab treatment has no adverse impact on sperm quality, quantity, or motility: A CARE-MS substudy. Presented at 21st World Congress of Neurology, September, Vienna, Austria.
48. Mayer L. Casady L. Clayton G. Oyuela P. Margolin D. (2014) Alemtuzumab infusion-associated reactions and management in multiple sclerosis. J Infus Nurs 37: 250–258.
49. McCombe P. Achiron A. Giovannoni G. Brinar V. Margolin D. Palmer J. et al. (2014) Pregnancy outcomes in the alemtuzumab multiple sclerosis clinical development program. Presented at 2014 Joint Meeting of Americas Committee for Treatment and Research in Multiple Sclerosis and European Committee for Treatment and Research in Multiple Sclerosis, September, Boston, MA.
50. McDonald W. Compston A. Edan G. Goodkin D. Hartung H. Lublin F. et al. (2001) Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the Diagnosis of Multiple Sclerosis. Ann Neurol 50: 121–127.
51. Menge T. Stüve O. Kieseier B. Hartung H. (2014) Alemtuzumab: the advantages and challenges of a novel therapy in MS. Neurology 83: 87–97.
52. Meyer D. Coles A. Oyuela P. Purvis A. Margolin D. (2012) Case report of anti-glomerular basement membrane disease following alemtuzumab treatment of relapsing-remitting multiple sclerosis. Mult Scler Rel Disord 2: 60–63.
53. Miller T. Habek M. Coles A. Selmaj K. Margolin D. Palmer J. et al. (2014) Analysis of data from RRMS alemtuzumab-treated patients in the clinical program to evaluate incidence rates of malignancy. Presented at 2014 Joint Meeting of Americas Committee for Treatment and Research in Multiple Sclerosis and European Committee for Treatment and Research in Multiple Sclerosis, September, Boston, MA.
54. O'Connor P. Wolinsky J. Confavreux C. Comi G. Kappos L. Olsson T. et al. (2011) Randomized trial of oral teriflunomide for relapsing multiple sclerosis. N Engl J Med 365: 1293–1303.
55. Paintlia M. Paintlia A. Singh A. Singh I. (2011) Synergistic activity of interleukin-17 and tumor necrosis factor-alpha enhances oxidative stress-mediated oligodendrocyte apoptosis. J Neurochem 116: 508–521.
56. Polman C. O'Connor P. Havrdova E. Hutchinson M. Kappos L. Miller D. et al. (2006) A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 354: 899–910.
57. Polman C. Reingold S. Edan G. Filippi M. Hartung H. Kappos L. et al. (2005) Diagnostic criteria for multiple sclerosis: 2005 revisions to the ‘McDonald Criteria’. Ann Neurol 58: 840–846.
58. Rao S. Sancho J. Campos-Rivera J. Boutin P. Severy P. Weeden T. et al. (2012) Human peripheral blood mononuclear cells exhibit heterogeneous CD52 expression levels and show differential sensitivity to alemtuzumab mediated cytolysis. PloS ONE 7: e39416.
59. Tuohy O. Costelloe L. Hill-Cawthorne G. Bjornson I. Harding K. Robertson N. et al. (2014) Alemtuzumab treatment of multiple sclerosis: long-term safety and efficacy. J Neurol Neurosurg Psychiatry. 21 May 2014. [Epub ahead of print]. DOI: 10.1136/jnnp-2014–307721.
60. Turner M. Lamorte M. Chretien N. Havari E. Roberts B. Kaplan J. et al. (2013) Immune status following alemtuzumab treatment in human CD52 transgenic mice. J Neuroimmunol 261: 29–36.
61. Twyman C. Oyuela P. Palmer J. Margolin D. Dayan C. (2014) Thyroid autoimmune adverse events in patients treated with alemtuzumab for relapsing-remitting multiple sclerosis: four-year follow-up of the CARE-MS studies Neurology 82: P2.199.
62. Vermersch P. Czlonkowska A. Grimaldi L. Confavreux C. Comi G. Kappos L. et al. (2013) Teriflunomide versus subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis: a randomised, controlled phase 3 trial. Mult Scler 20: 705–716.
63. Viglietta V. Baecher-Allan C. Weiner H. Hafler D. (2004) Loss of functional suppression by CD4+CD25+ regulatory T cells in patients with multiple sclerosis. J Exp Med 199: 971–979.
64. Waggoner J. Martinu T. Palmer S. (2009) Progressive multifocal leukoencephalopathy following heightened immunosuppression after lung transplant. J Heart Lung Transplant 28: 395–398.
65. Wray S. Arnold D. Cohen J. Coles A. Confavreux C. Fox E. et al. (2013 a) Comparison of infection risk with alemtuzumab and SC IFNB-1a in patients with multiple sclerosis who experienced disease activity while on prior therapy (CARE-MS II). Neurology 80: P01.172.
66. Wray S. Arnold D. Cohen J. Coles A. Fox E. Hartung H. et al. (2013 b) Herpes infection risk reduced with acyclovir prophylaxis after alemtuzumab. Annual Meeting of the Consortium of Multiple Sclerosis Centers (CMSC), May–June, 2013, Orlando, FL, Poster DX60.
67. Wynn D. Arnold D. Coles A. Hartung H. Havrdova E. Selmaj K. et al. (2013) Detection, incidence, and management of glomerulonephritis in the alemtuzumab clinical development program. Presented at 29th Congress of the European Committee for Research and Treatment in Multiple Sclerosis, October, Copenhagen, Denmark.
68. Yamout B. Issa Z. Herlopian A. El Bejjani M. Khalifa A. Ghadieh A. et al. (2013) Predictors of quality of life among multiple sclerosis patients: a comprehensive analysis. Eur J Neurol 20: 756–764.
69. Zhang X. Tao Y. Chopra M. Ahn M. Marcus K. Choudhary N. et al. (2013) Differential reconstitution of T cell subsets following immunodepleting treatment with alemtuzumab (anti-CD52 monoclonal antibody) in patients with relapsing-remitting multiple sclerosis. J Immunol 191: 5867–5874.
70. Zozulya A. Wiendl H. (2008) The role of regulatory T cells in multiple sclerosis. Nat Clin Pract Neurol 4: 384–398.